SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Clin Transplant. 2006;20(4):496-503.

Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.

, , , , , , , , , , ,

제1저자 김인호 · 교신저자 김병국

소속 (1)
  1. Department of Internal Medicine, Seoul National University, College of Medicine, Seoul, Korea.

Abstract

We have conducted a direct comparison of the outcomes of reduced intensity and myeloablative conditioning in younger adults with hematological malignancies<50 yr. One hundred and five patients received transplants from human leukocyte antigen (HLA)-matched donors, via either reduced intensity (n=35) or myeloablative conditioning (n=70). The median ages of the reduced intensity and myeloablative groups were 36 and 33 yr (p=0.014). Neutrophil engraftment (i.e. time to absolute neutrophil count>0.5x10(9)/L) occurred more rapidly in the reduced intensity group (median: 10 d; range: 0-21 d) than in the myeloablative group (median: 18 d; range: 11-38 d; p<0.0001). The incidence of grades 2-4 acute graft-vs.-host disease were similar between the reduced intensity and myeloablative groups, at 17% vs. 24% respectively (p=0.40). The cumulative incidence of day 100 non-relapse mortality was 18% in the reduced intensity group, and 21% in the myeloablative group (p=0.88). The overall two-yr survival rates were 43% in the reduced intensity group, and 35% in the myeloablative group (p=0.72). In conclusion, reduced intensity transplantation yielded outcomes comparable with those of myeloablative transplantation in patients under 50 with hematological malignancies.

그 밖의 정보
출판 형태
Controlled Clinical Trial, Journal Article
저널
Clinical transplantation · ISSN 0902-0063
MeSH
Adult · Antineoplastic Combined Chemotherapy Protocols / therapeutic use · Female · Graft vs Host Disease · Hematologic Neoplasms / mortality / therapy · Hematopoietic Stem Cell Transplantation / methods · Histocompatibility Testing · Humans · Male · Melphalan / administration & dosage · Middle Aged · Survival Analysis · Transplantation Conditioning · Transplantation, Homologous / physiology · Treatment Outcome
Substances
Melphalan